Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan

Bloodstream infections (BSIs) are a critical concern in pediatric onco-hematological patients undergoing chemotherapy or hematopoietic stem cell transplantation (HSCT), leading to a major impact on morbidity, long-term hospitalization, and mortality. We retrospectively analyzed 202 BSIs in 145 patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Ibrahim Ahmed Saleh Murshed, Lizhen Zhao, Wenzhi Zhang, Yuhong Yin, Ying Li, Yun Peng, Hongbo Chen, Xiaoyan Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Cellular and Infection Microbiology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcimb.2024.1480952/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846141558132310016
author Ibrahim Ahmed Saleh Murshed
Lizhen Zhao
Wenzhi Zhang
Yuhong Yin
Ying Li
Yun Peng
Hongbo Chen
Xiaoyan Wu
author_facet Ibrahim Ahmed Saleh Murshed
Lizhen Zhao
Wenzhi Zhang
Yuhong Yin
Ying Li
Yun Peng
Hongbo Chen
Xiaoyan Wu
author_sort Ibrahim Ahmed Saleh Murshed
collection DOAJ
description Bloodstream infections (BSIs) are a critical concern in pediatric onco-hematological patients undergoing chemotherapy or hematopoietic stem cell transplantation (HSCT), leading to a major impact on morbidity, long-term hospitalization, and mortality. We retrospectively analyzed 202 BSIs in 145 patients, consisting of 128 with hematological malignancies, one with a solid tumor, and 16 with non-malignant hematological diseases. We collected data on patient demographics, clinical characteristics, pathogen distribution, and antimicrobial pathogen susceptibility. Gram-positive infections were the most frequent at (58.4%), followed by gram-negative (41%), and fungal infections (0.5%). Particularly, the majority of these infections occurred during the induction phase of chemotherapy, where 94 (46.5%) BSI episodes were recorded, predominantly in neutropenic patients (88.3%). The consolidation phase experienced lower BSIs (11.8%); among these patients (54.1%) were non-neutropenic. BSIs observed in (23.7%) of patients in the maintenance phase, with a higher proportion (66.6%) being neutropenic. Among the 7 patients who underwent HSCT, BSIs occurred in (4.9%) cases, mainly (70%) due to neutropenia. The most prevalent pathogens were Staphylococcus epidermidis (19.8%), Staphylococcus hominis (16.3%), and Escherichia coli (8.4%). The study highlights the critical need for vigilant monitoring and customized infection management strategies to enhance patient outcomes across chemotherapy phases and HSCT.
format Article
id doaj-art-ecd2fa4a2d9f49668c0bcc10de1aee6e
institution Kabale University
issn 2235-2988
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cellular and Infection Microbiology
spelling doaj-art-ecd2fa4a2d9f49668c0bcc10de1aee6e2024-12-04T06:46:04ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882024-12-011410.3389/fcimb.2024.14809521480952Bloodstream infections in pediatric hematology/oncology patients: a single-center study in WuhanIbrahim Ahmed Saleh MurshedLizhen ZhaoWenzhi ZhangYuhong YinYing LiYun PengHongbo ChenXiaoyan WuBloodstream infections (BSIs) are a critical concern in pediatric onco-hematological patients undergoing chemotherapy or hematopoietic stem cell transplantation (HSCT), leading to a major impact on morbidity, long-term hospitalization, and mortality. We retrospectively analyzed 202 BSIs in 145 patients, consisting of 128 with hematological malignancies, one with a solid tumor, and 16 with non-malignant hematological diseases. We collected data on patient demographics, clinical characteristics, pathogen distribution, and antimicrobial pathogen susceptibility. Gram-positive infections were the most frequent at (58.4%), followed by gram-negative (41%), and fungal infections (0.5%). Particularly, the majority of these infections occurred during the induction phase of chemotherapy, where 94 (46.5%) BSI episodes were recorded, predominantly in neutropenic patients (88.3%). The consolidation phase experienced lower BSIs (11.8%); among these patients (54.1%) were non-neutropenic. BSIs observed in (23.7%) of patients in the maintenance phase, with a higher proportion (66.6%) being neutropenic. Among the 7 patients who underwent HSCT, BSIs occurred in (4.9%) cases, mainly (70%) due to neutropenia. The most prevalent pathogens were Staphylococcus epidermidis (19.8%), Staphylococcus hominis (16.3%), and Escherichia coli (8.4%). The study highlights the critical need for vigilant monitoring and customized infection management strategies to enhance patient outcomes across chemotherapy phases and HSCT.https://www.frontiersin.org/articles/10.3389/fcimb.2024.1480952/fullbacteremiahematologic neoplasmmicroorganismneutropeniapediatric
spellingShingle Ibrahim Ahmed Saleh Murshed
Lizhen Zhao
Wenzhi Zhang
Yuhong Yin
Ying Li
Yun Peng
Hongbo Chen
Xiaoyan Wu
Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan
Frontiers in Cellular and Infection Microbiology
bacteremia
hematologic neoplasm
microorganism
neutropenia
pediatric
title Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan
title_full Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan
title_fullStr Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan
title_full_unstemmed Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan
title_short Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan
title_sort bloodstream infections in pediatric hematology oncology patients a single center study in wuhan
topic bacteremia
hematologic neoplasm
microorganism
neutropenia
pediatric
url https://www.frontiersin.org/articles/10.3389/fcimb.2024.1480952/full
work_keys_str_mv AT ibrahimahmedsalehmurshed bloodstreaminfectionsinpediatrichematologyoncologypatientsasinglecenterstudyinwuhan
AT lizhenzhao bloodstreaminfectionsinpediatrichematologyoncologypatientsasinglecenterstudyinwuhan
AT wenzhizhang bloodstreaminfectionsinpediatrichematologyoncologypatientsasinglecenterstudyinwuhan
AT yuhongyin bloodstreaminfectionsinpediatrichematologyoncologypatientsasinglecenterstudyinwuhan
AT yingli bloodstreaminfectionsinpediatrichematologyoncologypatientsasinglecenterstudyinwuhan
AT yunpeng bloodstreaminfectionsinpediatrichematologyoncologypatientsasinglecenterstudyinwuhan
AT hongbochen bloodstreaminfectionsinpediatrichematologyoncologypatientsasinglecenterstudyinwuhan
AT xiaoyanwu bloodstreaminfectionsinpediatrichematologyoncologypatientsasinglecenterstudyinwuhan